Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.15
MNK's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 0.15 )
MNK' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.15

Equity to Asset 0.25
MNK's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 0.25 )
MNK' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.65
Current: 0.25

0.25
0.65
Interest Coverage 7.43
MNK's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 7.43 )
MNK' s 10-Year Interest Coverage Range
Min: 7.43   Max: 470.4
Current: 7.43

7.43
470.4
Z-Score: 1.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.55
MNK's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 5.55 )
MNK' s 10-Year Operating margin (%) Range
Min: 6.57   Max: 11.91
Current: 5.55

6.57
11.91
Net-margin (%) 2.90
MNK's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 2.90 )
MNK' s 10-Year Net-margin (%) Range
Min: 2.67   Max: 7.45
Current: 2.9

2.67
7.45
ROE (%) 5.01
MNK's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 5.01 )
MNK' s 10-Year ROE (%) Range
Min: 4.68   Max: 7.11
Current: 5.01

4.68
7.11
ROA (%) 1.23
MNK's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 1.23 )
MNK' s 10-Year ROA (%) Range
Min: 1.65   Max: 4.64
Current: 1.23

1.65
4.64
ROC (Joel Greenblatt) (%) 7.51
MNK's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 7.51 )
MNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.6   Max: 16.47
Current: 7.51

9.6
16.47
» MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MNK Guru Trades in Q3 2013

Chuck Royce 351,005 sh (New)
Pioneer Investments 122,851 sh (New)
John Paulson 5,640,000 sh (New)
Vanguard Health Care Fund 500,325 sh (New)
Mario Gabelli 13,360 sh (New)
Eric Mindich 900,000 sh (New)
» More
Q4 2013

MNK Guru Trades in Q4 2013

Jim Simons 279,900 sh (New)
Jean-Marie Eveillard 187 sh (New)
Chuck Royce 402,005 sh (+14.53%)
Eric Mindich 900,000 sh (unchged)
Vanguard Health Care Fund 500,325 sh (unchged)
John Paulson 5,640,000 sh (unchged)
Mario Gabelli Sold Out
Pioneer Investments Sold Out
» More
Q1 2014

MNK Guru Trades in Q1 2014

Steven Cohen 557,066 sh (New)
Pioneer Investments 121,494 sh (New)
Paul Tudor Jones 360,100 sh (New)
Jean-Marie Eveillard 187 sh (unchged)
Eric Mindich Sold Out
Vanguard Health Care Fund Sold Out
John Paulson 5,636,800 sh (-0.06%)
Jim Simons 254,100 sh (-9.22%)
Chuck Royce 178,505 sh (-55.6%)
» More
Q2 2014

MNK Guru Trades in Q2 2014

Mario Gabelli 2,656 sh (New)
Richard Perry 134,322 sh (New)
Chase Coleman 729,373 sh (New)
Paul Singer 916,000 sh (New)
John Paulson 6,724,800 sh (+19.3%)
Jean-Marie Eveillard 187 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 120,663 sh (-0.68%)
Jim Simons 238,900 sh (-5.98%)
Paul Tudor Jones 308,900 sh (-14.22%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 Add 19.3%0.37%$60.28 - $82.7 $ 86.7720%6724800
Richard Perry 2014-06-30 New Buy0.3%$60.28 - $82.7 $ 86.7720%134322
Mario Gabelli 2014-06-30 New Buy$60.28 - $82.7 $ 86.7720%2656
Vanguard Health Care Fund 2014-03-31 Sold Out 0.08%$50.7 - $72.81 $ 86.7739%0
Jean-Marie Eveillard 2013-12-31 New Buy$42.01 - $53.47 $ 86.7782%187
Mario Gabelli 2013-12-31 Sold Out $42.01 - $53.47 $ 86.7782%0
John Paulson 2013-09-30 New Buy1.6%$41.51 - $47.16 $ 86.7798%5640000
Vanguard Health Care Fund 2013-09-30 New Buy0.08%$41.51 - $47.16 $ 86.7798%500325
Mario Gabelli 2013-09-30 New Buy$41.51 - $47.16 $ 86.7798%13360
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 75.10
MNK's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 75.10 )
MNK' s 10-Year P/E(ttm) Range
Min: 35.03   Max: 75.75
Current: 75.1

35.03
75.75
P/B 3.80
MNK's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 3.80 )
MNK' s 10-Year P/B Range
Min: 1.95   Max: 3.82
Current: 3.8

1.95
3.82
P/S 2.30
MNK's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 2.30 )
MNK' s 10-Year P/S Range
Min: 1.11   Max: 2.21
Current: 2.3

1.11
2.21
PFCF 28.00
MNK's PFCF is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 28.00 )
MNK' s 10-Year PFCF Range
Min: 21.68   Max: 45.83
Current: 28

21.68
45.83
EV-to-EBIT 54.10
MNK's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 54.10 )
MNK' s 10-Year EV-to-EBIT Range
Min: 20.1   Max: 54.6
Current: 54.1

20.1
54.6
Current Ratio 2.58
MNK's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 2.58 )
MNK' s 10-Year Current Ratio Range
Min: 2.15   Max: 2.61
Current: 2.58

2.15
2.61
Quick Ratio 1.96
MNK's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 1.96 )
MNK' s 10-Year Quick Ratio Range
Min: 1.11   Max: 1.96
Current: 1.96

1.11
1.96

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.41
MNK's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 1.41 )
MNK' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.29
Current: 1.41

0.75
1.29
Earnings Yield (Greenblatt) 1.80
MNK's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MNK: 1.80 )
MNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 5
Current: 1.8

1.8
5

Business Description

Industry: »
Compare: » details
Traded in other countries:MCD.Germany
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company's products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company's nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems' products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.
» More Articles for NYSE:MNK

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Should You Buy Actavis? Mar 18 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 


More From Other Websites
Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher Sep 18 2014
Novo Nordisk's Tresiba Effective in Children & Adolescents Sep 17 2014
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote Sep 15 2014
Spin-Off ETF Looks to Get Back to Old Ways Sep 12 2014
The Zacks Analyst Blog Highlights: Mylan, Abbott Laboratories, Mallinckrodt, Gilead Sciences and... Sep 12 2014
Can Mallinckrodt public limited (MNK) Keep the Earnings Streak Alive This Quarter? Sep 12 2014
NPS Pharmaceuticals (NPSP) Shoots Up Ahead of FDA Panel Sep 11 2014
Mylan to Acquire U.S. Rights to Arixtra for up to $300M Sep 11 2014
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal Sep 10 2014
Endocyte (ECYT) Worth Watching: Stock Soars 17% Sep 10 2014
Mallinckrodt (MNK) Shares March Higher, Can It Continue? Sep 08 2014
Canada Stocks to Watch: Bombardier, Nuvo Research, Athabasca Oil and more Sep 08 2014
New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief Sep 08 2014
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% Sep 08 2014
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint Sep 05 2014
Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and... Sep 05 2014
10 Stocks Billionaire John Paulson Loves in 2014 Sep 04 2014
Mallinckrodt Pharmaceutical’s MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination,... Sep 04 2014
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Gains 14.8% Sep 04 2014
Stocks End Mixed; Mallinckrodt Clears Buy Point Sep 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK